Applying lessons learned from anti-endotoxin therapy

Silver GM , Fink MP Possible roles for anti- or pro-inflammatory therapies in the management of sepsis. Surg Clin N Am 1994; 74: 711-723.

Office of Planning & Extramural Programs and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics; Hospital Infections Program, Center for Infectious Diseases, Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987 . Morbid Mortal Weekly Rep 1990; 39: 31-34.

Lowry SF Sepsis and its complications: clinical definitions and therapeutic prospects . Crit Care Med 1994; 22: S1-S2.

Thijs LG Sepsis criteria and selection of patients for immunotherapy. In: Levin J, van Deventer SJH , vander Poll T, Sturek A. (eds) Bacterial Endotoxins. Basic Science to Anti-Sepsis Strategies. Proceedings of the Fourth International Conference on Endotoxins, Amsterdam, The Netherlands, August 1993. Progress in Clinical and Biological Research , Vol. 388. New York: Wiley-Liss, 1994: 407-415.

Hoffman WD , Natanson C. Endotoxin in septic shock. Anesth Analg 1993 ; 77: 613-614.

Young LS Gram-negative sepsis. In: Mandell GL , Douglas RG , Bennett John E , (eds) Principles and Practices of Infectious Diseases . 3rd edn. New York: Churchill Livingstone 1990: 611-635.

Ziegler EJ , McCutchen JA , Fierer J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 20: 1225-1250.

Danner RL , Elin RJ , Flosseini BS et al. Endotoxemia in human septic shock. Chest 1991; 99: 165-175.

Brandtzaeg P. , Kierulf P. , Gaustad P. et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.

Suffredini AF , Fromm RE , Parker MM et al. The cardiovascular response to normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287.

VanDervant AL , Danner RL Antiendotoxin approaches to septic shock therapy . Crit Care Med 1994; 22: 539-541.

Wood DM , Parent JB , Gazzano-Santoro H. et al. Reactivity of monoclonal antibody ES® with endotoxin. I. Binding to lipid A and rough lipopolysaccharides. Circ Shock 1992; 38: 55-62.

Parent JB , Gazzano-Santoro H. , Wood DM et al. Reactivity of monoclonal antibody E5® with endotoxin. II. Binding to short-and long-chain smooth lipopolysaccharides. Circ Shock 1992; 38: 63-73.

Romulo R. , Palardy JE , Opal S. Efficacy of antiendotoxin monoclonal antibody E5 alone or in combination with ciprofloxin in neutropenic rats with pseudomonas sepsis. J Infect Dis 1993; 167: 126-130.

Greenberg RN , Wilson KM , Kung AY , Wedel NI , Gorelick KJ Observations using antiendotoxin antibody (E5@) as adjunctive therapy in humans with suspected, serious Gram-negative sepsis. Crit Care Med, 1992; 20: 730-735.

Greenman RI , Schein Rmh , Martin MA et al. A controlled clinical trial of ES® murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266: 1097-1102.

Bone RC , Balk RC , Cerra FB et al. ACCP/SCCM Consensus Conference: Definitions for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.

Ziegler EJ , Fisher CJ , Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991 ; 324: 429-436.

Fisher Jr CJ , Dhainaut J-F. , Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-1843.

Saravolatz LD , Wherry JC , Spooner C. et al. Clinical safety, tolerability and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha. J Infect Dis 1994; 169:214-217.